- Home
- LTRN vs INKT Comparison
LTRN vs INKT Comparison
Compare LTRN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- INKT
- Stock Information
- Founded
- LTRN 2013
- INKT 2017
- Country
- LTRN United States
- INKT United States
- Employees
- LTRN N/A
- INKT N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- LTRN Health Care
- INKT Health Care
- Exchange
- LTRN Nasdaq
- INKT Nasdaq
- Market Cap
- LTRN 36.1M
- INKT 31.2M
- IPO Year
- LTRN 2020
- INKT 2021
- Fundamental
- Price
- LTRN $3.32
- INKT $7.26
- Analyst Decision
- LTRN Strong Buy
- INKT Strong Buy
- Analyst Count
- LTRN 1
- INKT 2
- Target Price
- LTRN $25.00
- INKT $37.50
- AVG Volume (30 Days)
- LTRN 67.8K
- INKT 5.4K
- Earning Date
- LTRN 05-15-2025
- INKT 05-15-2025
- Dividend Yield
- LTRN N/A
- INKT N/A
- EPS Growth
- LTRN N/A
- INKT N/A
- EPS
- LTRN N/A
- INKT N/A
- Revenue
- LTRN N/A
- INKT N/A
- Revenue This Year
- LTRN N/A
- INKT N/A
- Revenue Next Year
- LTRN N/A
- INKT N/A
- P/E Ratio
- LTRN N/A
- INKT N/A
- Revenue Growth
- LTRN N/A
- INKT N/A
- 52 Week Low
- LTRN $2.55
- INKT $4.56
- 52 Week High
- LTRN $6.12
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- LTRN 47.70
- INKT 48.58
- Support Level
- LTRN $2.85
- INKT $6.98
- Resistance Level
- LTRN $3.48
- INKT $7.36
- Average True Range (ATR)
- LTRN 0.26
- INKT 0.31
- MACD
- LTRN 0.01
- INKT 0.03
- Stochastic Oscillator
- LTRN 53.41
- INKT 43.65
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.